A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation

NCT07678593 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

222

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors Cancer
Pancreatic Ductal Adenocarcinoma
RAS Mutation

Interventions

DRUG: GFH276
DRUG: Cetuximab
DRUG: Nab paclitaxel
DRUG: Gemcitabine
DRUG: Fluorouracil
DRUG: Leucovorin
DRUG: Irinotecan
DRUG: Oxaliplatin

Sponsor

Genfleet Therapeutics (Shanghai) Inc.